Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer

The ALK tyrosine kinase inhibitor (TKI), crizotinib, shows significant activity in patients whose lung cancers harbor ALK fusions but its efficacy is limited by variable primary responses and acquired resistance. In work arising from the intriguing clinical observation of a patient with ALK fusion+...

Descripción completa

Detalles Bibliográficos
Autores principales: Lovly, Christine M., McDonald, Nerina T., Chen, Heidi, Ortiz-Cuaran, Sandra, Heukamp, Lukas C., Yan, Yingjun, Florin, Alexandra, Ozretić, Luka, Lim, Diana, Wang, Lu, Chen, Zhao, Chen, Xi, Lu, Pengcheng, Paik, Paul K., Shen, Ronglai, Jin, Hailing, Buettner, Reinhard, Ansén, Sascha, Perner, Sven, Brockmann, Michael, Bos, Marc, Wolf, Jürgen, Gardizi, Masyar, Wright, Gavin M., Solomon, Benjamin, Russell, Prudence A., Rogers, Toni-Maree, Suehara, Yoshiyuki, Red-Brewer, Monica, Tieu, Rudy, de Stanchina, Elisa, Wang, Qingguo, Zhao, Zhongming, Johnson, David H., Horn, Leora, Wong, Kwok-Kin, Thomas, Roman K., Ladanyi, Marc, Pao, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159407/
https://www.ncbi.nlm.nih.gov/pubmed/25173427
http://dx.doi.org/10.1038/nm.3667

Ejemplares similares

Ejemplares similares